Logan Lutton

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

An alarming amount of COVID-19 disinformation is prevalent even from physicians.

An expected rise in COVID-19 cases in combination with other preventable diseases could overwhelm the healthcare system.

A new survey identifies what executives think could be the biggest disruptions in the next year for hospitals and health care groups.